Form 4: MaxCyte EVP Thomas M. Ross Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Thomas M. Ross, EVP of Global Sales at MaxCyte, Inc., executed stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On July 8, 2024, Thomas M. Ross, the EVP of Global Sales at MaxCyte, Inc., exercised options to acquire 19,802 shares of common stock at a price of $1.641 per share and sold the same amount at a weighted average price of $4.029.
- On July 9, 2024, Ross exercised options to acquire 13,531 shares of common stock at a price of $1.641 per share and sold the same amount at a weighted average price of $4.034.
- The transactions were executed under a Rule 10b5-1 trading plan adopted on March 19, 2024.
- Following these transactions, Ross directly owns 25,000 shares of common stock and holds options for 33,334 shares.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider trading activity under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.
Stakeholder Impact
- Shareholders may be interested in insider trading activity as an indicator of management's confidence in the company.
- The transactions are unlikely to have a significant impact on other stakeholders.
Key Dates
| Date | Description |
|---|---|
| March 19, 2024 | Date the Reporting Person adopted a Rule 10b5-1 trading plan |
| July 8, 2024 | Date of option exercise and stock sale |
| July 9, 2024 | Date of option exercise and stock sale |
| July 10, 2024 | Date of signature on the Form 4 filing |
| January 20, 2030 | Expiration date of the Employee Stock Options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.